This bill amends section 1903(i) of the Social Security Act to prohibit the use of Federal Medicaid matching funds for administrative expenditures associated with providing health benefits to noncitizens who are not lawful permanent residents and are ineligible for Medicaid due to immigration status. The prohibition includes an explicit carve-out permitting federal payment for costs tied to establishing or operating systems intended to ensure compliance with the prohibition.
The Act also requires the HHS Inspector General to deliver a report within 180 days describing how states separate and finance those administrative costs, the systems they use to enforce eligibility limits, whether states use provider taxes or intergovernmental transfers to cover the non‑Federal share, and how supplying covered outpatient drugs to these noncitizens interacts with Medicaid drug-pricing programs (Medicaid Drug Rebate Program and 340B). The change shifts fiscal responsibility for certain administrative activities and compels federal oversight of state practices and potential drug-price effects.
At a Glance
What It Does
It inserts a new paragraph into 42 U.S.C. 1396b(i) that bars federal matching payments for administration tied to providing health benefits to noncitizens who lack satisfactory immigration status, while allowing federal payment for systems used to enforce that bar. It also directs the HHS Inspector General to report to Congress within 180 days on state accounting, compliance mechanisms, financing approaches, and impacts on drug-pricing programs.
Who It Affects
State Medicaid agencies and their contractors that administer programs or separate administrative functions for noncitizen populations; states that operate state-funded health programs for noncitizens ineligible for Medicaid; providers serving those populations; and HHS OIG, which must prepare the mandated report.
Why It Matters
The bill reassigns federal-state financial risk for administrative activities related to ineligible noncitizens and creates a near-term compliance and reporting requirement that could reveal common funding workarounds (like provider taxes or intergovernmental transfers) and unintended interactions with Medicaid and 340B drug-pricing rules.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The statutory change targets the Federal Medical Assistance Percentage (FMAP) side of Medicaid by forbidding federal participation in the administrative costs that accompany providing health benefits to noncitizens who are ineligible due to immigration status. Practically, states will still be able to operate programs that deliver services to those populations, but the federal government will not reimburse the administrative overhead tied to those efforts, except when the expense is for systems specifically set up to make sure the prohibition is followed.
Because the text permits federal payment for costs “attributable to the establishment or operation of a system designed to ensure compliance,” states cannot be completely prevented from receiving federal dollars for certain eligibility-verification infrastructure. That carve-out is narrow: it focuses on systems to prevent improper federal payment rather than funding the broader administrative work of delivering benefits to the ineligible individuals themselves.The bill also leverages oversight: it instructs the HHS Inspector General to study how states separate administrative spending for Medicaid versus state-funded programs for ineligible noncitizens, to inventory the procedures states use to ensure compliance with federal restrictions, to describe how states finance the non-federal share (including whether they turn to provider taxes or intergovernmental transfers), and to analyze whether providing drugs purchased under Medicaid rebate or 340B programs to those noncitizens affects average manufacturer price calculations.
That report is due within 180 days of enactment and is explicitly targeted at identifying both accounting practices and program interactions that could offset or undermine the statute’s fiscal intent.Altogether, the bill shifts the immediate federal exposure for certain administrative costs onto states (or non-federal financing methods), while retaining a narrow federal funding path for compliance systems and asking the OIG to illuminate state behavior and drug-pricing consequences that could follow from the change.
The Five Things You Need to Know
The bill adds a new paragraph (28) to 42 U.S.C. 1396b(i) prohibiting Federal Medicaid funding for administrative costs associated with providing health benefits to noncitizens who lack satisfactory immigration status.
It expressly allows federal payment for costs tied to establishing or operating systems intended to ensure compliance with the prohibition, creating a limited exception for eligibility‑verification infrastructure.
The prohibition applies to administrative costs, not explicitly to the direct payment of health benefits, meaning the statutory change targets reimbursement of program administration rather than an outright ban on state-funded services.
The HHS Inspector General must submit a report to Congress within 180 days detailing how affected states separate and finance those administrative costs, the compliance procedures they use, and whether states employ provider taxes or intergovernmental transfers to fund the non‑Federal share.
The OIG report must include an analysis of whether covered outpatient drugs provided to these noncitizens under the Medicaid Drug Rebate Program or 340B affect the average manufacturer price for drugs and whether excluding such drugs would lower AMP.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — 'Protect Medicaid Act'
This is a one-line naming provision that designates the bill as the Protect Medicaid Act. It has no operative effect but is the caption under which the amendments and reporting requirement are organized.
Prohibit Federal reimbursement for admin costs tied to ineligible noncitizens
The bill modifies the list of prohibitions in 1903(i) by inserting a new paragraph that bars federal matching payments for administrative expenses associated with providing health benefits to noncitizens who are not lawful permanent residents and are ineligible for Medicaid under the statute’s immigration-status rules. The language frames the restriction around 'administration'—so the focus is on who pays for program operations, eligibility screens, case management, and claims-processing activities connected to these populations.
Federal payment allowed for systems to enforce the prohibition
The inserted paragraph includes a carve-out that prevents the prohibition from being read to bar federal payment for costs 'attributable to the establishment or operation of a system designed to ensure compliance' with the prohibition. That has two practical consequences: first, states retain a path to federal support for building eligibility-verification or accounting systems; second, the language narrows the exception to compliance-related systems rather than broader administrative activity, which will require states to allocate costs carefully in their accounting systems.
HHS Inspector General reporting requirement
Section 3 requires the HHS OIG to report within 180 days on several discrete topics: how states separate administrative costs for Medicaid versus state-funded health benefits for ineligible noncitizens; what procedures and systems states use to ensure they do not use federal funds improperly; the financing methods states employ to cover the non‑Federal share (with explicit attention to provider taxes and intergovernmental transfers); and a two-part drug-program analysis examining whether these noncitizens receive drugs purchased under Medicaid rebate or 340B programs and whether that practice affects average manufacturer price calculations. The reporting items are operationally detailed and intended to surface accounting practices and program interactions that could blunt or shift the statute’s fiscal impact.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal government / taxpayers — The statutory bar reduces the scope of federal matching payments for administrative activities tied to ineligible noncitizens, shifting near‑term fiscal exposure away from the federal budget.
- States that already isolate compliance infrastructure — States that maintain separate eligibility-verification or compliance systems can still claim federal funds for those costs under the carve-out, cushioning the bill’s financial effect where such infrastructure exists.
- HHS oversight functions — The OIG receives a focused mandate and new data that can improve federal visibility into state financing practices and drug‑pricing interactions, which can inform subsequent policy or audit actions.
Who Bears the Cost
- State Medicaid agencies — States that provide health benefits to noncitizens ineligible for Medicaid will likely need to cover the administrative costs for those programs with state funds or find alternative non‑federal financing mechanisms.
- Providers and local governments — Entities that serve as delivery points for state-funded noncitizen benefits may face reduced federal administrative reimbursements and could be drawn into state financing arrangements (for example, via provider taxes or intergovernmental transfers).
- Program contractors and eligibility vendors — Organizations that perform enrollment, case management, or claims-processing work tied to the affected populations may see contract revenue shift from federal reimbursement to state funding streams, complicating budgeting and audit expectations.
- HHS OIG and HHS program offices — The OIG must produce a detailed report on a tight timeline, and HHS program offices will need to analyze and potentially act on the findings, generating short-term workload increases.
Key Issues
The Core Tension
The bill pits federal fiscal control—preventing federal Medicaid dollars from subsidizing administration tied to ineligible noncitizens—against states’ operational and public-health needs: enforcing a strict funding boundary requires precise cost accounting and may force states to absorb costs or reconfigure programs, creating real trade-offs between budget discipline at the federal level and administrative feasibility and public‑health coverage at the state level.
The bill’s central operational challenge is one of accounting precision. Drawing a legally defensible and administrable line between 'administration' of Medicaid and the costs of delivering state-funded health services will require states to redesign cost-allocation methods and create auditable trails.
Medicaid cost accounting already separates administrative and service costs, but the new prohibition compels finer distinctions—especially where staff, IT systems, and clinics serve both eligible and ineligible populations. Disentangling mixed-use resources risks significant compliance costs and may produce disputes over allowable charges that invite federal audits or disallowances.
Another tension concerns the financing responses the bill anticipates and the OIG is asked to study. The statute does not bar states from funding the non‑Federal share of Medicaid-related activities through provider taxes, intergovernmental transfers, or other mechanisms, but those approaches carry their own legal and policy limits and can introduce perverse incentives.
The mandated analysis of Medicaid Drug Rebate and 340B interactions flags an underappreciated linkage: if states continue to supply drugs purchased under federal‑tied programs to ineligible noncitizens, rebate and AMP calculations could be affected, producing downstream price effects that the OIG must attempt to quantify. That exercise is methodologically fraught because AMP calculations depend on commercial sales data and manufacturer reporting that may not cleanly separate purchases linked to ineligible populations.
Finally, the statute risks chilling public-health programs with mixed constituencies. Where state or local public-health efforts target communicable disease control, pregnancy care, or emergency services that serve both eligible and ineligible individuals, the new funding rule could complicate program administration and deter states from broad protective measures unless they are willing to assume additional state costs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.